Home/Cases/Setterwalls has advised RhoVac in connection with a rights issue of approximatel... case / 25 Jun 2019Share / Setterwalls has advised RhoVac in connection with a rights issue of approximately SEK 180.9 million Setterwalls has advised RhoVac AB in connection with a rights issue of shares. Through the rights issue, RhoVac AB will receive gross proceeds of approximately SEK 180.9 million. RhoVac AB is a biotechnology company conducting research and development of immunotherapeutic drugs. The company’s main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. Contact: Ola Grahn, Ludwig Isell Lind af Hageby, Gustav Johansson Practice areas: Equity Capital Markets, Corporate law, Life Sciences Back Next article